Nephrology Dialysis Transplantation

NDT Advance Access originally published online on December 8, 2005
Nephrology Dialysis Transplantation 2006 21(2):268-272; doi:10.1093/ndt/gfi329

This Article Extract FREE Full Text (PDF) All Versions of this Article: 21/2/268    most recent gfi329v1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Archive Download to citation manager Search for citing articles in: ISI Web of Science (1) Request Permissions Disclaimer Google Scholar Articles by Kong, N. C. T. Search for Related Content PubMed PubMed Citation Articles by Kong, N. C. T. Social Bookmarking          What's this?

© The Author [2005]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

---

Editorial Comment

Pregnancy of a lupus patient—a challenge to the nephrologist

Norella C. T. Kong

Department of Medicine, Hospital University Kebangsaan Malaysia, Bandar Tun Razak, Kuala Lumpur, Malaysia

Correpondence and offprint requests to: Norella C. T. Kong, Department of Medicine, Hospital University Kebangsaan Malaysia, Bandar Tun Razak, 56000 Cheras, Kuala Lumpur, Malaysia. Email: norella{at}mail.hukm.ukm.my

Keywords: antiphospholipid syndrome; breast feeding; lupus nephritis; maternal and fetal outcomes; pregnancy; systemic lupus erythematosus

	Introduction

Top Introduction Fertility in SLE Effect of pregnancy on... Effect of SLE/LN on... Neonatal lupus Medications in pregnancy and... Conclusions References

 
Systemic lupus erythematosus (SLE) is an autoimmune disease with a predilection for women in their reproductive years. The influence of sex hormones on immunity is only beginning to be unravelled, is fascinating and may explain some of the contradictory reports of the effects of pregnancy on SLE and vice versa [1]. Clinical renal involvement occurs in up to 60–80% of lupus patients at some time point in their disease course. In the pre-steroid era, patients with severe lupus nephritis (LN) rarely survived beyond 2 years. With improved therapy of SLE/LN, survival and quality of life for lupus patients have improved vastly. This holds true even for the Asian region [2,3]. Thus, pregnancy and its outcome are a major concern for most SLE/LN patients and their doctors. Indeed, early reports of pregnancy outcome were quite dismal and underscored active disease at conception, hypertension, proteinuria, moderate renal dysfunction and the antiphospholipid syndrome as major risk factors for pregnancy losses, pregnancy-induced hypertension and pre-eclampsia, progressive renal function deterioration and even the occasional maternal death [1,4–8]. Newer issues relate to neonatal lupus, iatrogenic premature ovarian failure and breast feeding in the presence of immunosuppressive and other drug therapy for control of the underlying SLE/LN. All these complex issues pose a real challenge to the clinician and the nephrologist in particular.

	Fertility in SLE

Top Introduction Fertility in SLE Effect of pregnancy on... Effect of SLE/LN on... Neonatal lupus Medications in pregnancy and... Conclusions References

 
SLE patients are as fertile as the general population [7]. However, a pregnancy rate of 2.0–2.4 per patient has been reported not only during disease quiescence but also during active disease [3,4]. However, a lowered fertility rate is seen in patients with active disease when on high dose steroid therapy and in patients with established renal disease and moderate to severe renal failure [8]. The frequency of premature ovarian failure from cyclophosphamide used for the treatment of severe LN in the past two decades ranges from 11 to 59% and its risk is related to the age of the woman at start of therapy, duration and cumulative dose of cyclophosphamide [9–11].

	Effect of pregnancy on SLE/LN

Top Introduction Fertility in SLE Effect of pregnancy on... Effect of SLE/LN on... Neonatal lupus Medications in pregnancy and... Conclusions References

 
Whether lupus flares are more frequent during pregnancy remains controversial. Flares occur during all trimesters and often also occur post-partum. The frequency of flares ranges between 7 and 33% in women who have been in remission for at least 6 months prior to conception, but flares occur in up to 61–67% of patients if the disease was active at conception [4,5,12,13]. Prospective controlled studies have also reported contradictory results. Some authors found no difference in flares when pregnant SLE patients were compared with matched non-pregnant lupus controls [14,15]. Others reported a similar experience in their pregnant patients with inactive LN at conception [16,17]. Petri et al. and Ruiz-Istaroza et al. reported that pregnancy exacerbated lupus activity [18,19]. Overall most studies of patients with LN favour planned conception after 12–18 months of established remission [1,13,16,17]. Patients with anticardiolipin (aCLs) and/or a positive lupus anticoagulant (LA) are also at increased risk for flares [20,21]. Hence, a comprehensive pre-pregnancy screen should include lupus serology, serum complement levels, antiphospholipid antibodies (aPLs) and anti-Ro/SSA as well as anti-La/SSB antibodies, and is important in order to enable the nephrologists to provide appropriate prophylaxis.

	Effect of SLE/LN on pregnancy—obstetric and fetal outcome

Top Introduction Fertility in SLE Effect of pregnancy on... Effect of SLE/LN on... Neonatal lupus Medications in pregnancy and... Conclusions References

 
Historically, lupus pregnancy was associated with a high rate of obstetric and fetal complications. These include spontaneous abortion (20–30% both pre- and post-diagnosis of SLE), late miscarriage, intrauterine growth retardation, intrauterine death, preterm delivery and prematurity, with an overall fetal loss as high as 50% in unplanned pregnancies vs 13% in planned pregnancies [1,12,13,15,16].

Two major SLE complications influence pregnancy outcome, i.e. LN and the antiphospholipid syndrome.

Lupus nephritis
In the presence of LN, in past studies fetal losses ranged from 8 to 36%, miscarriages between 4 and 31%, and stillbirths or neonatal deaths between 4 and 23% [1,4,5,12,13]. The number of therapeutic terminations of pregnancies in these studies ranged from 0 to 19% and contributed to the total fetal wastage mentioned earlier. However, the activity of LN at conception greatly impacted on fetal losses which ranged between 25 and 57% in women with active LN vs 8–12.5% in those with quiescent renal disease [16–19].

How then should renal remission be defined? For the purpose of pregnancy, I believe it should be defined as past LN with stable renal function and with serum creatinine in the normal range or estimated glomerular filtration rate (eGFR) >60 ml/min/1.73 m², urinary red cells <5/high-power field, proteinuria <0.5 g/day and normal (ideally) serum C3 levels for at least 12–18 months and not 6 months only as proposed by others [1,13,16,17,22,23].

Pre-eclampsia vs active lupus nephritis
In patients with lupus, pregnancy is associated with an increased risk of pre-eclampsia of 13–32 vs 3–5% in healthy women [1,12,23–26] and the risk is particularly high if the patient has pre-existing hypertension, active LN or established chronic kidney disease and the antiphospholipid syndrome.

Pre-eclampsia is often difficult to distinguish from active LN. Pre-eclampsia is more likely in patients with antiphospholipid syndrome, past pre-eclampsia or in patients who have hypertension, LN or diabetes mellitus. Both conditions can present with hypertension, proteinuria, oedema and renal function deterioration, and may co-exist in the same patient. The distinction is important as management is vastly different. Active LN is more likely if baseline proteinuria doubles and is associated with active urine sediment (red cells, white cells and cellular casts), low serum complement and increased titres of anti-DNA antibodies [1,12,13,27,28]. Extrarenal lupus manifestations are helpful when present. In contrast, pre-eclampsia is more likely to be associated with thrombocytopenia, elevated serum liver enzymes and uric acid, as well as reduced urinary calcium excretion. Whilst treatment with steroids is mandatory in active LN, steroids will typically aggravate pre-eclampsia. In contrast to active lupus, proteinuria also declines rapidly with the delivery of the baby in pre-eclampsia.

Other renal risk factors
Apart from active LN and pre-eclampsia, other renal risk factors that impact on fetal outcome include proteinuria, impaired renal function and hypertension. Fetal loss ranged between 36 and 38% in lupus patients with pre-pregnant proteinuria 0.5 g/day compared with 13% in patients without proteinuria, suggesting that renal lupus should be fully quiescent before pregnancy is advisable [1,8,12,13,16].

Impaired renal function is another strong predictor of poor fetal outcome not only in lupus patients, but also in pregnant women with other renal diseases [1,8,12,13]. In patients on chronic maintenance haemodialysis, the success rate of pregnancy is <50% [29]. Successful pregnancy outcome in female LN patients transplanted for end-stage renal failure is comparable with that of renal recipients with other diagnoses (73% live births in SLE patients vs 76% in controls) [30].

Pre-existing hypertension, whether primary or resulting from steroids (and, recently, cyclosporin A and tacrolimus), past or present LN, as well as the presence of the antiphospholipid syndrome, are risk factors for pre-eclampsia with its attendant morbidity and mortality. Fetal loss occurred in 27% of normotensive women as compared with 70% in hypertensive mothers [6].

In the early 1990s, many studies reported that antiplatelet agents, especially low to moderate doses (75–100 mg) of aspirin, were useful to prevent pre-eclampsia in high-risk pregnancies [31]. Knight et al. reviewed 51 trials involving 36 500 women and showed a 19% reduction in the risk of pre-eclampsia with the use of antiplatelet agents. Overall, there was a 16% reduction in infant deaths and an 8% reduction in the risk of low birth weight babies [31]. Kincaid-Smith et al. reported that low-dose heparin was also useful for pre-eclampsia prophylaxis [32].

Antiphospholipid syndrome
The antiphospholipid syndrome is defined by the presence of aPLs in association with vascular thrombosis (arterial and venous) and/or recurrent abortions in women [33,34]. Other features include thrombocytopenia, neurological disease or livedo reticularis. Three different types of antibodies have been described, i.e. aCLs, circulating lupus anticoagulants and antibodies to the ß2 glycoprotein-I (anti-ß2GP-I).

In a review of some 14 000 women, Kutteh found that the prevalence of aPLs was 5% in normal obstetric patients, 24% in women undergoing in vitro fertilization and 37% in women with SLE [35]. A meta-analysis of 10 studies and 554 patients found that fetal loss was more common in women with than those without aPLs (38–59 vs 16–20%), LA (36 vs 13%) or aCLs (39 vs 18%) [36]. Although high-titre aPLs are the best immunological predictors of fetal loss in SLE patients, previous fetal loss is an even more powerful predictor [34].

The aPL confers increased risk of thrombosis in the mother and severe early onset of pre-eclampsia. It also causes a placental vasculopathy leading to fetal intrauterine growth retardation and death, although the precise pathogenetic mechanisms have yet to be fully defined [37,38]. Both Kutteh et al. and Rai et al. reported that aPL-positive lupus patients, if left untreated, will only have a live birth rate of 20%. With the use of low-dose aspirin, the live birth rate increased to 42–44%. With combined low-dose aspirin and low-dose low molecular weight heparin (LMWH), live birth rates almost doubled to 71–80% in their respective studies [39,40]. High-dose steroids were of no benefit. [41].

There is a dearth of data concerning Asian lupus patients. Mok et al. from Hong Kong reported a prevalence of 27% (n = 18) aPL positivity in their experience with 91 pregnancies in 66 pregnant lupus patients. Positivity for aPL was associated with recurrent miscarriages. The LA was the strongest predictor [odds ratio (OR) = 23.3, P = 0.002] [42]. In our own retrospective review of 197 pregnancies in 82 women, aPL screening was performed in 73 patients. LA was positive in 10 (17%) of 60 patients [23]. aCL, IgG and IgM antibody determinations were performed in all 73 patients, and 19 (26%) patients tested positive. Five patients were positive for all three aPLs; three of these suffered 11 fetal losses between them and one had no living child. Twenty-four (33%) of these aPL-positive patients had the antiphospholipid syndrome. There was a significant association between fetal wastage and aPL (P<0.0001) and between the aPL and LN (P<0.02). Thus, our experience concurs with that of most published studies.

	Neonatal lupus

Top Introduction Fertility in SLE Effect of pregnancy on... Effect of SLE/LN on... Neonatal lupus Medications in pregnancy and... Conclusions References

 
Anti-Ro/SSA and anti-La/SSB antibodies are present in some 30–50% of SLE patients in most reported series including our own [43–45]. These IgG antibodies cross the placenta to cause neonatal lupus in 5% of babies born to these mothers. Subsequent children have a 15–25% risk. Anti-Ro antibodies confer a 1–2% risk, whereas anti-La antibodies confer a 5% risk [44]. The majority of the affected babies suffer a transient and often mild lupoid rash lasting 3–6 months. Other clinical manifestations include immune thrombocytopenia, autoimmune haemolytic anaemia and cholestatic hepatitis. The most severe complication is congenital heart block (CHB). CHB is diagnosed by fetal bradycardia at 18–23 weeks. Some 20% of the affected infants die in the neonatal period and most survivors require permanent pacemakers. Dexamethasone (which crosses the placenta) and plasmapheresis provided short-term benefits only. Intravenous immunoglobulins have been reported to be useful, but numbers are small [44]. Hence, all lupus patients contemplating pregnancy should also have their anti-Ro/SSA and anti-La/SSB status determined. Affected fetuses should be referred to the paediatric cardiologist for close monitoring.

	Medications in pregnancy and the puerperium

Top Introduction Fertility in SLE Effect of pregnancy on... Effect of SLE/LN on... Neonatal lupus Medications in pregnancy and... Conclusions References

 
The goals of therapy are to maintain the mother with SLE/LN in disease remission, provide prophylaxis against the aPL-asociated thrombotic complications, prevent and treat hypertension and pre-eclampsia, as well as optimize fetal growth and well being. The mother should be counselled and prepared in advance for pregnancy.

Maintenance hydroxychloroquine at 200 mg daily has been demonstrated to be safe and reduces flares, fetal wastage, intrauterine growth retardation and fetal distress. It is also safe for breast feeding [46–48]. Low to moderate dose aspirin, low-dose or therapeutic dose heparin (LMWH) should be instituted for prophylaxis against pre-eclampsia and thrombosis in the aPL-positive patients and in patients at risk for pre-eclampsia. For past severe LN, the immunosuppressive therapy should be switched in advance to appropriate agents. In particular, azathioprine (1–1.5 mg/kg/day), low-dose cyclosporin A (2 mg/kg/day) and low-dose steroids (7.5–10 mg daily) are safe [13,49,50]. However, except for children of mothers on low-dose steroids (<15 mg/day), breast feeding is inadvisable. Medications must be avoided which can cause birth defects, adverse reactions or are excreted in breast milk. These include cyclophosphamide, methotrexate, mycophenolate mofetil, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, long-acting non-steroidal anti-inflammatory drugs (NSAIDs) and warfarin (first and third trimesters) [13,48–50].

	Conclusions

Top Introduction Fertility in SLE Effect of pregnancy on... Effect of SLE/LN on... Neonatal lupus Medications in pregnancy and... Conclusions References

 
Pregnancy in a lupus patient, especially after severe LN, continues to pose a major challenge to the nephrologist. Albeit fraught with potential risks and complications, current pregnancy outcome is definitely more optimistic and gratifying when planned to occur during disease remission and under close supervision by an experienced, dedicated, multidisciplinary team. Prophylactic measures against the aPL-associated vasculopathy and against pre-eclampsia are available and achieve a high rate of success. Nonetheless, vigilance for disease flares, pregnancy-induced hypertension, pre-eclampsia and the rare fetus with CHB should be maintained, and adequate facilities for the care of preterm babies are crucial.

Conflict of interest statement. None declared.

	References

Top Introduction Fertility in SLE Effect of pregnancy on... Effect of SLE/LN on... Neonatal lupus Medications in pregnancy and... Conclusions References

 

1. Moroni G, Ponticelli C. Pregnancy after lupus nephritis. Lupus 2005; 14: 89–94[Abstract/Free Full Text]
2. Kong NCT. SLE activity measures and prognosis. Malaysian J Dermatol 1996; 9: 15–24
3. Kong NCT. Editorial: systemic lupus erythematosus in Southeast Asia. J Am Med Assoc Southeast Asia Oct 1993; 8–10
4. Hayslett JP, Lynn RI. Effect of pregnancy in patients with lupus nephropathy. Kidney Int 1980; 18: 207–220[ISI][Medline]
5. Bobrie G, Liote F, Houillier P et al. Pregnancy in lupus nephritis and related disorders. Am J Kidney Dis 1987; 9: 339–343[ISI][Medline]
6. Oviasu E, Hicks J, Cameron JS. The outcome of pregnancy in women with lupus nephritis. Lupus 1991; 1: 19–25[Abstract/Free Full Text]
7. Khamashta MA, Hughes GRV. Pregnancy in SLE. Curr Opin Rheumatol 1996; 8: 424–429[Medline]
8. Hou SH, Grossman SD, Madias NE. Pregnancy in women with renal disease and moderate renal insufficiency. Am J Med 1985; 78: 185–194[CrossRef][ISI][Medline]
9. Boumpas DT, Austin HA, Vaughn EM et al. Risk for sustained amenorrhoea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med 1993; 119: 366–369[Abstract/Free Full Text]
10. Mok CC, Lau CS, Woon S et al. Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy. Arthritis Rheum 1998; 41: 831–837[CrossRef][ISI][Medline]
11. Park JC, Park YB, Jung S et al. Risk of ovarian failure and pregnancy outcome in patients with lupus nephritis treated with intravenous cyclophosphamide pulse therapy. Lupus 2004; 13: 569–574[Abstract/Free Full Text]
12. Mok CC, Wong RWS. Pregnancy in systemic lupus erythematosus. Postgrad Med J 2001; 77: 157–165[Abstract/Free Full Text]
13. Moroni G, Ponticelli C. The risk of pregnancy in patients with lupus nephritis. J Nephrol 2003; 16: 161–167[ISI][Medline]
14. Lockshin MD, Reinitz E, Druzin ML et al. Lupus pregnancy. Case–control prospective study demonstrating absence of lupus exacerbation during or after pregnancy. Am J Med 1984; 77: 893–898[CrossRef][ISI][Medline]
15. Urowitz MB, Gladman DD, Farewell VT et al. Lupus and pregnancy studies. Arthritis Rheum 1993; 36: 1392–1397[ISI][Medline]
16. Cervera R, Font J, Carmona F et al. Pregnancy outcomes in systemic lupus erythematosus: good news for the new millennium. Autoimmun Rev 2002; 1: 354–359[CrossRef][Medline]
17. Huong DI, Wechsler B, Vauthier-Brouzes D et al. Pregnancy in past or present lupus nephritis: a study of 32 pregnancies from a single centre. Ann Rheum Dis 2001 60: 599–604
18. Petri M, Howard D, Repke J. Frequency of lupus flare in pregnancy. The Hopkins Lupus Pregnancy Center experience. Arthritis Rheum 1991; 34: 1538–1545[ISI][Medline]
19. Ruiz-Irastorza G, Lima F, Alves J et al. Increased rate of lupus flare during pregnancy and the puerperium: a prospective study of 78 pregnancies. Br J Rheumatol 1996; 35: 133–138[Abstract/Free Full Text]
20. Rahman P, Gladman DD, Urowitz MB. Clinical predictors of fetal outcome in systemic lupus erythematosus. J Rheumatol 1998; 25: 1526–1530[ISI][Medline]
21. Martinez-Rueda JO, Arce-Saluas CA, Kraus A et al. Factors associated with fetal losses in severe SLE. Lupus 1996; 5: 113–119[ISI][Medline]
22. Boumpas DT, Balow JE. Outcome criteria for lupus nephritis trials: a critical overview. Lupus 1998; 7: 622–629[Abstract/Free Full Text]
23. Kong NCT. Lupus nephritis and pregnancy (Plenary). Proceedings of the 13th Annual Congress of Nephrology, 16 April 2005, Manila, Phillipines
24. Burkett G. Lupus nephropathy and pregnancy. Clin Obstet Gynecol 1985; 28: 310–323[ISI][Medline]
25. Julkunen H, Kaaja R, Palosuo T et al. Pregnancy in lupus nephropathy. Acta Obstet Gynecol Scand 1993; 72: 258–263[ISI][Medline]
26. Sibai BM, Gordon T, Thom E et al. Risk factors for pre-eclampsia in healthy nulliparous women: a prospective multicenter study. The National Institute of Child Health and Human Development Network of Maternal–Fetal Medicine Units. Am J Obstet Gynecol 1995; 172: 642–648[CrossRef][ISI][Medline]
27. Buyon JP, Crowsten BN, Morris M et al. Serum complement values (C3 & C4) to differentiate between systemic lupus activity and pre-eclampsia. Am J Med 1986; 21: 194–200
28. Repke JT. Hypertensive disorders of pregnancy. Differentiating pre-eclampsia from active SLE. J Reprod Med 1998; 43: 35
29. Hou, S. Pregnancy in chronic renal insufficiency and end-stage renal disease. Am J Kidney Dis 1999; 233: 235
30. McGrory CH, McCloskey LJ, DeHoratius RJ et al. Pregnancy outcomes in female renal recipients: a comparison of systemic lupus erythematosus with other diagnoses. Am J Transplant 2003; 3: 35–42[CrossRef][ISI][Medline]
31. Knight M, Duley L, Handerson Smart DI. Antiplatelet agents for preventing pre-eclampsia (Cochrane Review). The Renal Health Library; 2005
32. Kincaid-Smith P, North RA, Fairly KF et al. Prevention of pre-eclampsia in high risk women with renal disease in a prospective randomized trial of heparin dipyridamole. Nephrology 1995; 1: 297–300
33. Khamashta MA. Management of thrombosis and pregnancy loss in antiphospholipid syndrome. Lupus 1998; 7: S162–S165[ISI][Medline]
34. Lockshin MD. Pregnancy loss and antiphospholipid antibodies. Lupus 1998; 7: S86–S89[Medline]
35. Kutteh WH. Antiphospholipid antibodies and reproduction. J Reprod Immunol 1997; 35: 15
36. McNeil HP, Chesterman CN, Krulis SA. Immunology and clinical importance of antiphospholipid antibodies. Adv Immunol 1991; 49: 193[ISI][Medline]
37. Levy RA, Avaad E, Oliviera J et al. Placental pathology in antiphospholipid syndrome. Lupus 1998; 7: S81–S85[Medline]
38. Magid MS, Kaplan S, Sammaritano LR et al. Placental pathology in SLE: a prospective study. Am J Obstet Gynecol 1998; 79: 226–234
39. Kutteh WH. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol 1996; 174: 1584–1589[ISI][Medline]
40. Rai R, Cohen H, Dave M et al. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with antiphospholipid antibodies. Br Med J 1997; 314: 253–257[Abstract/Free Full Text]
41. Cowchock FS, Reece EA, Balaban D et al. Repeated fetal losses associated with antiphospholipid antibodies: a collaborative randomized trial comparing prednisone with low-dose heparin treatment. Am J Obstet Gynecol 1992; 166: 1318–1323[ISI][Medline]
42. Mok MY, Leung PY, Lao TH et al. Clinical predictors of fetal and maternal outcome in Chinese patients with SLE. Ann Rheum Dis 2004; 63: 1705–1706[Free Full Text]
43. Brucato A, Frassi M, Franceschini F et al. Risk of congenital complete heart block in new borns of mothers with anti-RO/SSA antibodies detected by counter immuno-electrophoresis. A prospective study of 100 women. Arthritis Rheum 2001; 44: 1723–1727[CrossRef][ISI][Medline]
44. Buyon JP, Calucy RM. Neonatal lupus syndromes. Curr Opin Rheumatol 2003; 15: 535–541[CrossRef][ISI][Medline]
45. Azizah MR, Ainol SS, Kong NCT et al. Demographic, clinical and immunological features of 134 Malaysian patients with systemic lupus erythematosus. Int Med J 2001; 8: 45–50
46. The Canadian Hydroxychloroquine Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med 1991; 324: 150–154[Abstract]
47. Parke Al, Rothfield NF. Antimalarial drugs in pregnancy—the North American experience. Lupus 1996; 5: S67–S69[Medline]
48. Committee on Drugs, American Academy of Pediatrics. The transfer of drugs and other chemicals into human milk. Pediatrics 1994; 93: 137–150[Abstract/Free Full Text]
49. Ramsey-Goldman R, Mientus JM, Kutzer JE et al. Pregnancy outcome in women with systemic lupus erythematosus treated with immunosuppressive drugs. J Rheumatol 1993; 20: 1152–1157[ISI][Medline]
50. Bar Oz B, Hackman R, Einsson T et al. Pregnancy outcome after cycloporine therapy during pregnancy: a meta-analysis. Transplantation 2001; 71: 1051–1055[CrossRef][ISI][Medline]

Received for publication: 8. 9.05
Accepted in revised form: 20.11.05

CiteULike    Connotea    Del.icio.us    What's this?

This article has been cited by other articles:

				E. Imbasciati, A. Tincani, G. Gregorini, A. Doria, G. Moroni, G. Cabiddu, and D. Marcelli Pregnancy in women with pre-existing lupus nephritis: predictors of fetal and maternal outcome Nephrol. Dial. Transplant., June 18, 2008; (2008) gfn348v1. [Abstract] [Full Text] [PDF]

				M. Gayed and C. Gordon Pregnancy and rheumatic diseases Rheumatology, November 1, 2007; 46(11): 1634 - 1640. [Abstract] [Full Text] [PDF]

This Article Extract FREE Full Text (PDF) All Versions of this Article: 21/2/268    most recent gfi329v1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Archive Download to citation manager Search for citing articles in: ISI Web of Science (1) Request Permissions Disclaimer Google Scholar Articles by Kong, N. C. T. Search for Related Content PubMed PubMed Citation Articles by Kong, N. C. T. Social Bookmarking          What's this?

Online ISSN 1460-2385 - Print ISSN 0931-0509

Copyright © 2008 European Renal Association - European Dialysis and Transplant Assoc

Oxford Journals Oxford University Press

• Site Map
• Privacy Policy
• Frequently Asked Questions

Other Oxford University Press sites: Oxford University Press Oxford Journals Japan American National Biography Booksellers' Information Service Children's Fiction and Poetry Children's Reference Corporate & Special Sales Dictionaries Dictionary of National Biography Digital Reference English Language Teaching Higher Education Textbooks Humanities International Education Unit Law Medicine Music Online Products Oxford English Dictionary Reference Rights and Permissions Science School Books Social Sciences Very Short Introductions World's Classics